Primary cutaneous T-cell non-Hodgkin lymphoma

Related records

Broader conditions (21)

• Cancer
• Cancer or benign tumor
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Hematologic disorder
• Hematopoietic and lymphoid cell neoplasm
• Hematopoietic and lymphoid system neoplasm
• Human disease
• Integumentary system cancer
• Integumentary system disorder
• Lymphoid hemopathy
• Lymphoid neoplasm
• Lymphoma
• Neoplasm
• Neoplastic disease or syndrome
• Primary cutaneous lymphoma
• Primary organ-specific lymphoma
• Skin cancer
• Skin disorder

Narrower conditions (8)

• Folliculotropic mycosis fungoides
• Granulomatous slack skin disease
• Localized pagetoid reticulosis
• Mycosis fungoides
• Mycosis fungoides variant
• Primary cutaneous anaplastic large cell lymphoma
• Primary cutaneous gamma-delta t-cell lymphoma
• Sezary syndrome

Trials (253)

• 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
• 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
• 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
• 506U78 in Treating Patients With Lymphoma
• 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
• A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
• A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
• A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
• A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL
• A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
• A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
• A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
• A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).
• A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
• A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
• A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
• A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
• A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
• A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors

Approved drugs (5)

• Bexarotene
• Denileukin diftitox
• Mechlorethamine hydrochloride
• Romidepsin
• Vorinostat

Drugs in development (71)

• 6-O-benzylguanine Phase 1
• Acimtamig Phase 1
• Agatolimod sodium Phase 1
• Aldesleukin Phase 1
• Atezolizumab Phase 2
• Belinostat Phase 2
• Brentuximab vedotin Phase 3
• Carfilzomib Phase 1
• Carmustine Phase 1
• Cobomarsen Phase 2
• Copanlisib hydrochloride Phase 1
• Curcumin Phase 2
• Cyanocobalamin Phase 1
• Daporinad Phase 2
• Daratumumab Phase 1
• Decitabine Phase 1
• Dexamethasone Phase 1
• Dimethyl fumarate Phase 2
• Doxorubicin Phase 1
• Doxycycline Early phase 1

Other linked drugs (1)

• Methoxsalen